# Halozyme Therapeutics (HALO) — Analyst Forecast

HALO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/halo/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 8 | 2 | 1 | 11 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $78.00 | $106.00 | $130.00 | 6 |

Last price $121.51 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 13, 2026 | TD Cowen | Maintained | Buy | $130.00 |
| Oct 8, 2026 | HC Wainwright & Co. | Maintained | Buy | $130.00 |
| Oct 8, 2026 | JP Morgan | Maintained | Neutral | $78.00 |
| Sep 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $115.00 |
| Aug 7, 2026 | HC Wainwright & Co. | Maintained | Buy | $115.00 |
| Aug 7, 2026 | Wells Fargo | Maintained | Equal-Weight | $95.00 |
| Aug 7, 2026 | Citizens | Maintained | Market Outperform | $93.00 |
| Aug 7, 2026 | TD Cowen | Maintained | Buy | $105.00 |
| Aug 7, 2026 | Leerink Partners | Upgraded | Market Perform → Outperform | $110.00 |
| Jul 21, 2026 | HC Wainwright & Co. | Maintained | Buy | $95.00 |
| May 12, 2026 | Morgan Stanley | Maintained | Overweight | $93.00 |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | $95.00 |
| Feb 19, 2026 | Wells Fargo | Maintained | Equal-Weight | $75.00 |
| Feb 19, 2026 | Benchmark | Maintained | Buy | $90.00 |
| Jan 8, 2026 | TD Cowen | Maintained | Buy | $90.00 |
| Dec 19, 2025 | HC Wainwright & Co. | Maintained | Buy | $90.00 |
| Nov 28, 2025 | HC Wainwright & Co. | Maintained | Buy | $90.00 |
| Nov 18, 2025 | Goldman Sachs | Maintained | Neutral | $56.00 |
| Nov 4, 2025 | Citizens | Maintained | Market Outperform | $92.00 |
| Oct 27, 2025 | JP Morgan | Maintained | Neutral | $65.00 |

## Frequently Asked Questions

### What is the price target for HALO stock?

The average 12-month analyst price target for Halozyme Therapeutics (HALO) is $106.00, with a high estimate of $130.00 and a low of $78.00, across 6 analysts.

### Is HALO a buy, sell, or hold?

Analysts covering Halozyme Therapeutics currently average a Buy rating: 8 buy, 2 hold and 1 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for HALO?

The average price target of $106.00 implies 12.76% downside from the last price of $121.51.

### What is the latest analyst rating on HALO?

On Oct 13, 2026, TD Cowen maintained Halozyme Therapeutics at Buy with a price target of $130.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).